Travere prices upsized USD 475 million 0.5% convertible senior notes offering due 2032

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

0.00

  • Travere Therapeutics priced an upsized USD 475 million offering of 0.50% convertible senior notes due 2032, lifting the deal from the previously announced USD 400 million.
  • Notes convert at an initial price of about USD 64.90 per share, with an initial conversion rate of 15 shares per USD 1,000 principal amount.
  • Net proceeds estimated at about USD 460 million, rising to about USD 508.5 million if underwriters exercise a USD 50 million over-allotment option.
  • About USD 350.9 million of proceeds earmarked to repurchase about USD 221.4 million principal amount of outstanding 2.25% senior convertible notes due 2029.
  • Offering expected to close May 11, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.